{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:22:23Z","timestamp":1794964943335,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tamoxifen resistance remains a significant challenge in the endocrine therapy of estrogen receptor-positive (ER+) breast cancer. Cancer-associated fibroblasts (CAFs) facilitate therapeutic resistance through exosome secretion, yet the role of CAF-derived long non-coding RNAs (lncRNAs) in tamoxifen resistance remains underexplored. This study investigates the mechanism by which CAF-secreted exosomal lncRNA modulates tamoxifen resistance in ER\u2009+\u2009breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      CAFs from ER\u2009+\u2009breast cancer patients and normal fibroblasts (NFs) from healthy control were isolated and cultured ex vivo. Exosomes were extracted from the supernatant of cultured cells using ultracentrifugation. RNA sequencing identified PRKCQ-AS1 as a candidate lncRNA, validated in tamoxifen-sensitive and resistant tumors. Functional assays (qPCR, RNA-seq, dual-luciferase reporter, and in vivo xenografts) elucidated the role of PRKCQ-AS1\/miR-200a-3p\/MKP1 axis in tamoxifen resistance. Prognostic correlations were assessed in clinical cohorts (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009471) and TCGA\/GEO datasets.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LncRNA PRKCQ-AS1 was markedly upregulated in tamoxifen-resistant tumor samples and was associated with poor prognosis in tamoxifen-treated ER\u2009+\u2009breast cancer patients but not in those treated with aromatase inhibitors. Exosomal PRKCQ-AS1 derived from CAFs transferred to ER\u2009+\u2009breast cancer cells, suppressing tamoxifen-induced apoptosis via MKP1 upregulation. Mechanistically, PRKCQ-AS1 acted as a molecular sponge for miR-200a-3p, relieving miR-200a-3p-mediated repression of MKP1. Elevated MKP1 inactivated the MAPK\/JNK pathway, attenuating apoptosis. In vivo, PRKCQ-AS1 overexpression accelerated ER\u2009+\u2009breast tumor growth despite tamoxifen treatment. TGF-\u03b2-driven CAF transformation upregulated PAX5, a transcription factor enhancing PRKCQ-AS1 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study identifies CAF-derived exosomal LncRNA PRKCQ-AS1 as a key mediator of tamoxifen resistance via the miR-200a-3p\/MKP1 axis. Targeting this pathway may offer novel therapeutic strategies to overcome endocrine resistance in ER\u2009+\u2009breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03529-x","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:34:09Z","timestamp":1759235649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cancer-associated fibroblast promotes tamoxifen resistance in estrogen receptor positive breast cancer via exosomal LncRNA PRKCQ-AS1\/miR-200a-3p\/MKP1 axis-mediated apoptosis suppression"],"prefix":"10.1186","volume":"44","author":[{"given":"Chenghui","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"3529_CR1","doi-asserted-by":"crossref","unstructured":"Nolan E, Lindeman GJ. and J. E. Visvader. Deciphering Breast Cancer: From Biology to the Clinic. CELL. 2023;186(8):1708-28.","DOI":"10.1016\/j.cell.2023.01.040"},{"key":"3529_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semcancer.2020.12.004","volume":"82","author":"OA Sukocheva","year":"2022","unstructured":"Sukocheva OA, Lukina E, Friedemann M, Menschikowski M, Hagelgans A, Gjumrakch Aliev. The crucial role of epigenetic regulation in breast cancer Anti-Estrogen resistance: current findings and future perspectives. Sem Cancer Biol. 2022;82:35\u201359.","journal-title":"Sem Cancer Biol"},{"issue":"17","key":"3529_CR3","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1200\/JCO.23.00455","volume":"41","author":"A Laws","year":"2023","unstructured":"Laws A, Punglia RS. Endocrine therapy for primary and secondary prevention after diagnosis of High-Risk breast lesions or preinvasive breast cancer. J Clin Oncol. 2023;41(17):3092\u201399.","journal-title":"J Clin Oncol"},{"key":"3529_CR4","doi-asserted-by":"publisher","first-page":"216443","DOI":"10.1016\/j.canlet.2023.216443","volume":"579","author":"H Guo","year":"2023","unstructured":"Guo H, Tan YQ, Huang X, Zhang S, Basappa B, Zhu T, Pandey V, Peter E. Lobie. Small molecule Inhibition of TFF3 overcomes Tamoxifen resistance and enhances taxane efficacy in ER\u2009+\u2009Mammary carcinoma. Cancer Lett. 2023;579:216443.","journal-title":"Cancer Lett"},{"issue":"3","key":"3529_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10549-018-5023-4","volume":"173","author":"Ma\u0142gorzata Szostakowska","year":"2019","unstructured":"Szostakowska Ma\u0142gorzata, Tr\u0119bi\u0144ska-Stryjewska A, Grzybowska EA, Fabisiewicz A. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat. 2019;173(3):489\u201397.","journal-title":"Breast Cancer Res Treat"},{"key":"3529_CR6","doi-asserted-by":"crossref","unstructured":"He H, Sinha I, Haldosen RFL-A, Zhao FYC, Dahlman-Wright K. C-Jun\/AP-1 Overexpression Reprograms ER\u03b1 Signaling Related to Tamoxifen Response in ER\u03b1-positive Breast Cancer. ONCOGENE. 2018;37(19):2586\u2009\u2013\u2009600.","DOI":"10.1038\/s41388-018-0165-8"},{"issue":"3","key":"3529_CR7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"key":"3529_CR8","doi-asserted-by":"publisher","first-page":"216859","DOI":"10.1016\/j.canlet.2024.216859","volume":"591","author":"Q Qin","year":"2024","unstructured":"Qin Q, Yu R, Eriksson JE,. Cancer Lett. 2024;591:216859.","journal-title":"Cancer Lett"},{"issue":"5","key":"3529_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/cac2.12291","volume":"42","author":"D Hu","year":"2022","unstructured":"Hu D, Li Z, Zheng B, Lin X, Pan Y, Gong P, Zhuo W, Hu Y, Chen C, Chen L. Jichun zhou, and Linbo wang. Cancer-Associated fibroblasts in breast cancer: challenges and opportunities. Cancer Commun. 2022;42(5):401\u201334.","journal-title":"Cancer Commun"},{"key":"3529_CR10","doi-asserted-by":"crossref","unstructured":"Namee N, Mc, Lorraine OD. Extracellular vesicles and Anti-Cancer drug resistance. Biochimica et biophysica ACTA-reviews on cancer. 2018;1870(2):123\u201336.","DOI":"10.1016\/j.bbcan.2018.07.003"},{"issue":"1","key":"3529_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-019-0965-7","volume":"18","author":"S Maacha","year":"2019","unstructured":"Maacha S, Bhat AA, Jimenez L, Raza A, Haris M, Uddin S. Extracellular Vesicles-Mediated intercellular communication: roles in the tumor microenvironment and Anti-Cancer drug resistance. Mol Cancer. 2019;18(1):55.","journal-title":"Mol Cancer"},{"key":"3529_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/advs.202002518","volume":"7","author":"Y Gao","year":"2020","unstructured":"Gao Y, Li X, Zeng C, Liu C, Hao Q, Li W, Zhang K, Zhang W, Wang S, Zhao H, Li DFM, Zhang Y. Wei zhang, and Cun zhang. CD63\u2009+ cancer-Associated fibroblasts confer Tamoxifen resistance to breast cancer cells through Exosomal miR\u201022. Adv Sci. 2020;7:21.","journal-title":"Adv Sci"},{"key":"3529_CR13","doi-asserted-by":"publisher","first-page":"216747","DOI":"10.1016\/j.canlet.2024.216747","volume":"588","author":"J Sun","year":"2024","unstructured":"Sun J, Du R, Li X, Liu C, Wang D, He X, Li G, Zhang K, Wang S, Hao Q, Zhang Y, Li M, Gao Y, Zhang C. CD63(+) cancer-Associated fibroblasts confer CDK4\/6 inhibitor resistance to breast cancer cells by Exosomal miR-20. Cancer Lett. 2024;588:216747.","journal-title":"Cancer Lett"},{"key":"3529_CR14","doi-asserted-by":"crossref","unstructured":"Slack FJ, Arul M. Chinnaiyan. The Role of Non-Coding RNAs in Oncology. CELL. 2019;179(5):1033-55.","DOI":"10.1016\/j.cell.2019.10.017"},{"issue":"1","key":"3529_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12943-020-01181-x","volume":"19","author":"F Crudele","year":"2020","unstructured":"Crudele F, Bianchi N, Reali E, Galasso M, Agnoletto C, Stefano Volinia. The network of Non-Coding RNAs and their molecular targets in breast cancer. Mol Cancer. 2020;19(1):61.","journal-title":"Mol Cancer"},{"key":"3529_CR16","doi-asserted-by":"publisher","first-page":"216508","DOI":"10.1016\/j.canlet.2023.216508","volume":"581","author":"S Wu","year":"2024","unstructured":"Wu S, Lu J, Zhu H, Wu F, Mo Y, Xie L, Song C, Liu L, Xie X, Li Y. Huan lin, and Hailin tang. A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in Triple-Negative breast cancer. Cancer Lett. 2024;581:216508.","journal-title":"Cancer Lett"},{"key":"3529_CR17","doi-asserted-by":"publisher","first-page":"216907","DOI":"10.1016\/j.canlet.2024.216907","volume":"592","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Tan Y, Yuan J, Tang H, Zhang H, Tang Y, Xie Y, Wu L, Xie J, Xiao X, Li Y, Yanan Kong. CircLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer. Cancer Lett. 2024;592:216907.","journal-title":"Cancer Lett"},{"issue":"2","key":"3529_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.bcp.2013.10.020","volume":"87","author":"M Jiang","year":"2014","unstructured":"Jiang M, Huang O, Xie Z, Wu S, Zhang X, Shen A, Liu H, Chen X, Wu J, Lou Y, Mao Y. Kan sun, Shudong hu, Meiyu geng, and Kunwei shen. A novel long Non-Coding RNA-ARA: adriamycin resistance associated. Biochem Pharmacol. 2014;87(2):254\u201383.","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"3529_CR19","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41419-021-04409-w","volume":"12","author":"Z Yan","year":"2021","unstructured":"Yan Z, Sheng Z, Zheng Y, Feng R, Shi QXL, Li H, Yin C, Luo H, Hao C, Wang W, Zhang B. Cancer-Associated Fibroblast-Derived Exosomal miR-18b promotes breast cancer invasion and metastasis by regulating TCEAL7. Cell Death Dis. 2021;12(12):1120.","journal-title":"Cell Death Dis"},{"key":"3529_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jare.2021.09.009","volume":"37","author":"C Shang","year":"2022","unstructured":"Shang C, Li Y, He T, Liao Y, Du Q, Wang P, Qiao J, Guo H. The prognostic miR-532-5p-correlated ceRNA-mediated lipid droplet accumulation drives nodal metastasis of cervical cancer. J Adv Res. 2022;37:169\u201384.","journal-title":"J Adv Res"},{"issue":"5","key":"3529_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrg.2016.20","volume":"17","author":"DW Thomson","year":"2016","unstructured":"Thomson DW, Marcel E. Dinger. Endogenous MicroRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272\u201383.","journal-title":"Nat Rev Genet"},{"issue":"2","key":"3529_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2478\/jtim-2023-0084","volume":"11","author":"X Qiao","year":"2023","unstructured":"Qiao X, Ding Y, Altawil A, Yin Y, Wang Q, Wang W, Kang J. Roles of noncoding RNAs in chronic obstructive pulmonary disease. J Translational Intern Med. 2023;11(2):106\u201310.","journal-title":"J Translational Intern Med"},{"issue":"1","key":"3529_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41418-022-01049-1","volume":"30","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Shao Y, Hu W, Zhang J, Shi Y, Kong X, Jiang J. A novel long noncoding RNA SP100-AS1 induces radioresistance of colorectal cancer via sponging miR-622 and stabilizing ATG3. Cell Death Differ. 2023;30(1):111\u201324.","journal-title":"Cell Death Differ"},{"issue":"1","key":"3529_CR24","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1038\/ncomms4596","volume":"5","author":"K Wang","year":"2014","unstructured":"Wang K, Zhou BLL-Y, Liu F, Zhou Q-Y, Liu C-Y, Fan Y-Y, Pei-Feng, Li. CARL LncRNA inhibits Anoxia-Induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation. Nature Communications. 2014;5(1):3596.","journal-title":"Nature Communications"},{"issue":"1","key":"3529_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10555-010-9208-5","volume":"29","author":"KK Haagenson","year":"2010","unstructured":"Haagenson KK. The role of MAP kinases and MAP kinase Phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev. 2010;29(1):143\u201349.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"3529_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/ijms14010108","volume":"14","author":"Roc\u00edo Garc\u00eda-Becerra","year":"2013","unstructured":"Garc\u00eda-Becerra Roc\u00edo, Santos N, D\u00edaz L. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, MiRNAs and genetically based resistance. Int J Mol Sci. 2013;14(1):108\u201345.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3529_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ccell.2023.03.001","volume":"41","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhu S, Liu T, Zhang S, Lu J, Fan W, Lin L, Xiang T, Yang J, Zhao X, Xi Y, Ma Y, Cheng G, Lin D, Wu C. Epithelial cells activate fibroblasts to promote esophageal cancer development. Cancer Cell. 2023;41(5):903\u201318.","journal-title":"Cancer Cell"},{"issue":"1","key":"3529_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-024-01965-5","volume":"23","author":"W Ge","year":"2024","unstructured":"Ge W, Wang Y, Quan M, Mao T, Bischof EY, Xu H, Zhang X, Li S, Yue M, Ma J, Yang H, Wang L, Yu Z, Wang L, Jiujie Cui. Activation of the PI3K\/AKT signaling pathway by ARNTL2 enhances cellular Glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib. Mol Cancer. 2024;23(1):48.","journal-title":"Mol Cancer"},{"key":"3529_CR29","doi-asserted-by":"publisher","first-page":"100933","DOI":"10.1016\/j.drup.2023.100933","volume":"68","author":"C Zhu","year":"2023","unstructured":"Zhu C, Xie Y, Li Q, Zhang Z, Chen J, Zhang K, Xia X, Yu D, Chen D, Zhengyuan Yu, and, Chen J. CPSF6-mediated XBP1 3\u2019UTR shortening attenuates Cisplatin-Induced ER stress and elevates Chemo-Resistance in lung adenocarcinoma. Drug Resist Updates. 2023;68:100933.","journal-title":"Drug Resist Updates"},{"issue":"1","key":"3529_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12943-022-01605-w","volume":"21","author":"M Jiang","year":"2022","unstructured":"Jiang M, Qi F, Zhang K, Zhang X, Ma J, Xia S, Chen L, Yu Z, Chen J, Chen D. MARCKSL1\u20132 reverses Docetaxel-Resistance of lung adenocarcinoma cells by recruiting SUZ12 to suppress HDAC1 and elevate miR-200b. Mol Cancer. 2022;21(1):150.","journal-title":"Mol Cancer"},{"key":"3529_CR31","first-page":"217116","volume":"598","author":"C Yang","year":"2024","unstructured":"Yang C, Deng X, Tang Y, Tang H. Chenglai Xia Nat Prod Reverse Cisplatin Resist Hypoxic Tumor Microenvironment Cancer Letters. 2024;598:217116.","journal-title":"Chenglai Xia Nat Prod Reverse Cisplatin Resist Hypoxic Tumor Microenvironment CANCER LETTERS"},{"key":"3529_CR32","doi-asserted-by":"publisher","first-page":"100947","DOI":"10.1016\/j.drup.2023.100947","volume":"68","author":"R Du","year":"2023","unstructured":"Du R, Zhang X, Lu X, Ma X, Guo X, Shi C, Ren X, Ma X, He Y. Yuan gao, and Yunjiang liu. PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting Antibody-Dependent NK Cell-Mediated cytotoxicity. Drug Resist Updates. 2023;68:100947.","journal-title":"Drug Resist Updates"},{"key":"3529_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1126\/scitranslmed.adj5705","volume":"16","author":"G Fan","year":"2024","unstructured":"Fan G, Yu B, Tang L, Zhu R, Chen J, Zhu Y, Huang H, Zhou L, Liu J, Wang W, Tao Z, Zhang F, Yu S, Lu X, Cao Y, Du S, Li H, Li J, Zhang J, Ren H, Gires O, Liu H, Wang X, Qin J, Wang H. TSPAN8(+) myofibroblastic cancer-Associated fibroblasts promote chemoresistance in patients with breast cancer. Sci Transl Med. 2024;16:741.","journal-title":"Sci Transl Med"},{"issue":"3","key":"3529_CR34","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP,. JAMA-journal Am Med Association. 2019;321(3):288\u2013300.","journal-title":"JAMA-JOURNAL Am Med ASSOCIATION"},{"key":"3529_CR35","doi-asserted-by":"crossref","unstructured":"Kalluri R, Valerie S. LeBleu. The Biology, Function, and Biomedical Applications of Exosomes. Science. 2020;367(6478).","DOI":"10.1126\/science.aau6977"},{"issue":"4","key":"3529_CR36","first-page":"452","volume":"29","author":"AM Schmitt","year":"2016","unstructured":"Schmitt AM, Chang HY. Long Noncoding RNAs Cancer Pathways Cancer Cell. 2016;29(4):452\u201363.","journal-title":"Long Noncoding RNAs Cancer Pathways CANCER CELL"},{"issue":"5","key":"3529_CR37","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.32604\/or.2024.058256","volume":"33","author":"JIAHUI WANG","year":"2025","unstructured":"Wang Jiahui, Hongcheng GE Zhengyuanyu. Non-Coding RNAs as potential mediators of resistance to lung cancer immunotherapy and chemotherapy. Oncol Res. 2025;33(5):1033\u201354.","journal-title":"Oncol Res"},{"issue":"1","key":"3529_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-023-01765-3","volume":"22","author":"GS Raju","year":"2023","unstructured":"Raju GS, Rama E, Pavitra SS, Bandaru GL, Varaprasad GP, Nagaraju. Rama Rao malla, Yun Suk huh, and Young-Kyu han. HOTAIR: A potential metastatic, Drug-Resistant and prognostic regulator of breast cancer. Mol Cancer. 2023;22(1):65.","journal-title":"Mol Cancer"},{"key":"3529_CR39","doi-asserted-by":"crossref","unstructured":"Zheng R, Jia J, Guan L, Yuan H, Liu K, Liu C, Ye W, Liao Y, Lin S, Huang O. Long Noncoding RNA lnc-LOC645166 Promotes Adriamycin Resistance Via NF-\u03baB\/GATA3 Axis in Breast Cancer. Aging (Albany, NY.). 2020;12(10):8893\u2009\u2013\u2009912.","DOI":"10.18632\/aging.103012"},{"issue":"10","key":"3529_CR40","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1002\/jcb.29712","volume":"121","author":"G Cui","year":"2020","unstructured":"Cui G, Zhao HL, Li L. Long noncoding RNA PRKCQ-AS1 promotes CRC cell proliferation and migration via modulating miR\u20101287\u20105p\/YBX1 axis. J Cell Biochem. 2020;121(10):4166\u201375.","journal-title":"J Cell Biochem"},{"key":"3529_CR41","doi-asserted-by":"crossref","unstructured":"Zheng S, Fu W, Huang Q, Zhou J, Lu K, Gu J, Ma R, Guo G. LncRNA PRKCQ-AS1 regulates Paclitaxel resistance in Triple\u2010Negative breast cancer cells throughmiR\u2010361\u20105p\/PIK3C3 mediated autophagy. Clinical and experimental pharmacology and physiology. 2023;50(6):431\u201342.","DOI":"10.1111\/1440-1681.13758"},{"issue":"1","key":"3529_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-016-0530-6","volume":"15","author":"N Bartonicek","year":"2016","unstructured":"Bartonicek N, Maag JLV, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016;15(1):43.","journal-title":"Mol Cancer"},{"key":"3529_CR43","doi-asserted-by":"crossref","unstructured":"Kong Y, Yang L, Wei W, Lyu N, Zou Y, Gao G, Ou X, Xie X, Tang H. CircPLK1 Sponges miR-296-5p to Facilitate Triple-Negative Breast Cancer Progression. Epigenomics. 2019;11(10):1163-76.","DOI":"10.2217\/epi-2019-0093"},{"issue":"12","key":"3529_CR44","first-page":"1469","volume":"40","author":"Y Zou","year":"2019","unstructured":"Zou Y, Zheng S, Xiao W, Xie X, Yang A, Gao G, Xiong Z, Xue Z, Tang H, Xie X. CircRAD18 sponges miR-208a\/3164 to promote Triple-Negative breast cancer progression through regulating IGF1 and FGF2 expression. Carcinogenesis. 2019;40(12):1469\u201379.","journal-title":"Carcinogenesis"},{"key":"3529_CR45","doi-asserted-by":"crossref","unstructured":"Qiao Y, Jin T, Guan S, Cheng S, Wen S, Zeng H, Zhao M, Yang L, Wan X, Qiu Y, Li Q, Liu M, and Yixuan Hou. Long Non-Coding RNA Lnc-408 Promotes InvasionMetastasis of Breast Cancer Cell by Regulating LIMK1. Oncogene. 2021;40(24):4198\u2009\u2013\u2009213.","DOI":"10.1038\/s41388-021-01845-y"},{"key":"3529_CR46","doi-asserted-by":"crossref","unstructured":"Reznik SE, Tiwari AK, Chavda V, Ashby CR Jr. The Delivery of N-myc Downstream-Regulated Gene 2 (NDRG2) Self-Amplifying mRNA Via Modified Lipid Nanoparticles as a Potential Treatment for Drug-Resistant and Metastatic Cancers. Med Rev (2021). 2024;4(3):235\u2009\u2013\u200938.","DOI":"10.1515\/mr-2024-0004"},{"issue":"1","key":"3529_CR47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41420-023-01771-w","volume":"10","author":"L Wu","year":"2024","unstructured":"Wu L, Huang S, Tian W, Liu P, Xie Y, Qiu Y, Li X, Tang Y, Zheng S, Sun Y, Tang H, Du W, Tan W, Xie X. PIWI-interacting RNA-YBX1 inhibits proliferation and metastasis by the MAPK signaling pathway via YBX1 in Triple-Negative breast cancer. Cell Death Discovery. 2024;10(1):7.","journal-title":"Cell Death Discovery"},{"key":"3529_CR48","doi-asserted-by":"publisher","first-page":"553","DOI":"10.34133\/research.0553","volume":"7","author":"K Ganesan","year":"2024","unstructured":"Ganesan K, Xu C, Wu S, Sui Y, Du B, Zhang J, Gao F, Chen J, Hailin Tang. Ononin inhibits tumor bone metastasis and osteoclastogenesis by targeting Mitogen-Activated protein kinase pathway in breast cancer. Research. 2024;7:553.","journal-title":"Research"},{"issue":"8","key":"3529_CR49","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/cam4.772","volume":"5","author":"J Shen","year":"2016","unstructured":"Shen J, Zhang Y, Yu H, Shen B, Liang Y, Jin R, Liu X, Shi L, Cai X. Role of DUSP1\/MKP1 in tumorigenesis, tumor progression and therapy. Cancer Med. 2016;5(8):2061\u201368.","journal-title":"Cancer Med"},{"issue":"9","key":"3529_CR50","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1158\/0008-5472.CAN-06-2644","volume":"67","author":"GW Small","year":"2007","unstructured":"Small GW, Yue Y, Shi, Linda S, Higgins, Robert Z. Orlowski. Mitogen-Activated protein kinase Phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res. 2007;67(9):4459\u201366.","journal-title":"Cancer Res"},{"key":"3529_CR51","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1479-5876-12-16","volume":"12","author":"Y Gu","year":"2014","unstructured":"Gu Y, Chen T, Lopez E, Wu W, Wang X, Cao J, Teng L. The therapeutic target of Estrogen Receptor-Alpha36 in Estrogen-Dependent tumors. J Translational Med. 2014;12:16.","journal-title":"J Translational Med"},{"issue":"10","key":"3529_CR52","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/cdd.2012.41","volume":"19","author":"A Rininger","year":"2012","unstructured":"Rininger A, Dejesus C, Totten A, Wayland A, Halterman MW. MKP-1 antagonizes c\/ebpbeta activity and lowers the apoptotic threshold after ischemic injury. Cell Death Differ. 2012;19(10):1634\u201343.","journal-title":"Cell Death Differ"},{"issue":"12","key":"3529_CR53","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1002\/ijc.31657","volume":"143","author":"Y Wang","year":"2018","unstructured":"Wang Y, Ding X, He HHY, Lu Z, Wu P, Tian L, Xia T, Yin J, Yuan H, Shi G, Liu D, Jiang K, Miao Y. Long Non-Coding RNA Lnc\u2010PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC\u20103. Int J Cancer. 2018;143(12):3143\u201354.","journal-title":"Int J Cancer"},{"issue":"1","key":"3529_CR54","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13048-020-00750-4","volume":"13","author":"M Pei","year":"2020","unstructured":"Pei M, Li ZX, Zhao. Dysregulation of lnc-SNHG1 and miR-216b-5p correlate with chemoresistance and indicate poor prognosis of serous epithelial ovarian cancer. J Ovarian Res. 2020;13(1):144.","journal-title":"J Ovarian Res"},{"issue":"1","key":"3529_CR55","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12935-019-1000-1","volume":"19","author":"M Shademan","year":"2019","unstructured":"Shademan M, Salanghuch AN, Zare K, Zahedi M, Foroughi MA, Rezayat KA. Hooman Mosannen mozaffari, Kamran ghaffarzadegan, Ladan goshayeshi, and Hesam dehghani. Expression profile analysis of two antisense LncRNAs to improve prognosis prediction of colorectal adenocarcinoma. Cancer Cell Int. 2019;19(1):278.","journal-title":"Cancer Cell Int"},{"key":"3529_CR56","doi-asserted-by":"publisher","first-page":"710689","DOI":"10.3389\/fonc.2021.710689","volume":"11","author":"Meng-ke Fan","year":"2021","unstructured":"Fan Meng-ke, Zhang Guo-chuan, Chen W, Qi Li-li, Xie Ming-fang, Zhang Yue-yao. Ling wang, and Qi zhang. Siglec-15 promotes tumor progression in osteosarcoma via DUSP1\/MAPK pathway. Front Oncol. 2021;11:710689.","journal-title":"Front Oncol"},{"issue":"11","key":"3529_CR57","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/1535-7163.MCT-15-0920","volume":"15","author":"R Rincon","year":"2016","unstructured":"Rincon R, Zazo S, Chamizo C, Manso R, Gonzalez-Alonso P, Martin-Aparicio E, Cristobal I, Canadas C, Perona R, Lluch A, Eroles P, Garcia-Foncillas J, Albanell J, Rovira A, Madoz-Gurpide J. Rojo. C-Jun N-Terminal kinase inactivation by Mitogen-Activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer. Mol Cancer Ther. 2016;15(11):2780\u201390.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"3529_CR58","doi-asserted-by":"publisher","first-page":"s1024","DOI":"10.1158\/1078-0432.CCR-05-2127","volume":"12","author":"M Dowsett","year":"2006","unstructured":"Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S. Stephen francis, Geraldine walsh, and Roger a\u2019hern. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res. 2006;12(3):s1024\u201330.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03529-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03529-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03529-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:30:08Z","timestamp":1781609408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03529-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3529"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03529-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the independent Ethical Committees of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. All animal experiments were approved by the Institutional Animal Care and Use Committee of Shanghai Jiao Tong University School of Medicine (Shanghai, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}